CollPlant Partners with U.S. Logistics Center to Expand North American Market
- Market Expansion: CollPlant has established a partnership with a U.S.-based logistics center expected to become operational this quarter, aimed at enhancing distribution capabilities for its rhCollagen and BioInk products across the U.S. and Canada, thereby supporting its growing customer base.
- Innovation Breakthrough: CollPlant's rhCollagen has been utilized in research at Mayo Clinic to develop the first fully humanized 3D bioprinted skin model, providing a sustainable alternative to animal testing, showcasing its broad application potential in medical and aesthetic fields.
- Financial Improvement: CollPlant reported GAAP revenues of $77,000 for the third quarter, a significant increase from $4,000 in the same period last year, primarily driven by increased sales of rhCollagen products, indicating a gradual recovery in the market.
- Cost Control: CollPlant has implemented a cost reduction plan expected to reduce its workforce by approximately 25%, aimed at optimizing resource allocation and extending its cash runway to support future R&D and market expansion.
Trade with 70% Backtested Accuracy
Analyst Views on CLGN
About CLGN
About the author
Wall Street Analysts Adjust Ratings on Top Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market views and expectations for these companies.
- Market Reaction: While specific stocks were not mentioned, such rating changes typically influence investor decisions and may lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying PI stock should pay attention to analysts' opinions to better assess potential investment risks and returns.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, especially in a rapidly changing market environment.
D. Boral Capital Upholds Buy Rating for CollPlant Biotechnologies (CLGN)
Analyst Recommendation: D. Boral Capital has maintained a Buy recommendation for CollPlant Biotechnologies, with a projected one-year price target of $11.73/share, indicating a potential upside of 436.16% from its current price of $2.19/share.
Projected Revenue and EPS: CollPlant Biotechnologies is expected to see a significant increase in annual revenue, projected at $5,277 million, alongside a non-GAAP EPS forecast of 6.62.
Fund Sentiment: There has been a slight increase in institutional ownership, with 17 funds reporting positions in CollPlant, although total shares owned by institutions decreased by 19.63% over the last three months.
Shareholder Activity: Notable shareholders like Villere St Denis J & Co and AMH Equity have increased their holdings in CollPlant, while Renaissance Technologies has significantly reduced its stake.
D. Boral Capital Reiterates Buy Rating for CollPlant Biotechnologies with $12 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
CollPlant Partners with U.S. Logistics Center to Expand North American Market
- Market Expansion: CollPlant has established a partnership with a U.S.-based logistics center expected to become operational this quarter, aimed at enhancing distribution capabilities for its rhCollagen and BioInk products across the U.S. and Canada, thereby supporting its growing customer base.
- Innovation Breakthrough: CollPlant's rhCollagen has been utilized in research at Mayo Clinic to develop the first fully humanized 3D bioprinted skin model, providing a sustainable alternative to animal testing, showcasing its broad application potential in medical and aesthetic fields.
- Financial Improvement: CollPlant reported GAAP revenues of $77,000 for the third quarter, a significant increase from $4,000 in the same period last year, primarily driven by increased sales of rhCollagen products, indicating a gradual recovery in the market.
- Cost Control: CollPlant has implemented a cost reduction plan expected to reduce its workforce by approximately 25%, aimed at optimizing resource allocation and extending its cash runway to support future R&D and market expansion.
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Expansion of Operations: CollPlant is set to enhance its North American distribution of rhCollagen and BioInk products through a new partnership with a U.S.-based logistics center, which will improve operational efficiency and support its growing customer base.
Innovative Developments: The company has made significant strides in its dermal filler program and has reported successful preclinical results, including the creation of a fully humanized bioprinted skin model, showcasing the potential of its rhCollagen technology as a non-animal alternative for medical research.
Financial Performance: CollPlant reported a notable increase in revenues for the third quarter of 2025, driven by sales of rhCollagen-based products and a milestone payment from AbbVie, while also implementing cost reduction measures that include a workforce reduction of approximately 25%.
Future Plans: The company aims to prioritize its collaboration with AbbVie and continue advancing its dermal filler product candidate, while also seeking strategic partnerships for the development of its regenerative breast implant product.
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS
Financial Results Announcement: CollPlant Biotechnologies will report its third-quarter financial results for 2025 on November 26, 2025, before U.S. market opening.
Company Overview: CollPlant specializes in regenerative and aesthetic medicine, focusing on 3D bioprinting and products based on non-animal-derived rhCollagen for tissue regeneration.
Partnership with Allergan: In 2021, CollPlant entered a global commercialization agreement with Allergan, a leader in the dermal filler market, for the development of dermal and soft tissue fillers.
Contact Information: For further inquiries, CollPlant's Deputy CEO & CFO, Eran Rotem, and investor relations contact, Daniel Ferry, are available for communication.
Wall Street Analysts Adjust Ratings on Top Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market views and expectations for these companies.
- Market Reaction: While specific stocks were not mentioned, such rating changes typically influence investor decisions and may lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying PI stock should pay attention to analysts' opinions to better assess potential investment risks and returns.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, especially in a rapidly changing market environment.
D. Boral Capital Upholds Buy Rating for CollPlant Biotechnologies (CLGN)
Analyst Recommendation: D. Boral Capital has maintained a Buy recommendation for CollPlant Biotechnologies, with a projected one-year price target of $11.73/share, indicating a potential upside of 436.16% from its current price of $2.19/share.
Projected Revenue and EPS: CollPlant Biotechnologies is expected to see a significant increase in annual revenue, projected at $5,277 million, alongside a non-GAAP EPS forecast of 6.62.
Fund Sentiment: There has been a slight increase in institutional ownership, with 17 funds reporting positions in CollPlant, although total shares owned by institutions decreased by 19.63% over the last three months.
Shareholder Activity: Notable shareholders like Villere St Denis J & Co and AMH Equity have increased their holdings in CollPlant, while Renaissance Technologies has significantly reduced its stake.
D. Boral Capital Reiterates Buy Rating for CollPlant Biotechnologies with $12 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
CollPlant Partners with U.S. Logistics Center to Expand North American Market
- Market Expansion: CollPlant has established a partnership with a U.S.-based logistics center expected to become operational this quarter, aimed at enhancing distribution capabilities for its rhCollagen and BioInk products across the U.S. and Canada, thereby supporting its growing customer base.
- Innovation Breakthrough: CollPlant's rhCollagen has been utilized in research at Mayo Clinic to develop the first fully humanized 3D bioprinted skin model, providing a sustainable alternative to animal testing, showcasing its broad application potential in medical and aesthetic fields.
- Financial Improvement: CollPlant reported GAAP revenues of $77,000 for the third quarter, a significant increase from $4,000 in the same period last year, primarily driven by increased sales of rhCollagen products, indicating a gradual recovery in the market.
- Cost Control: CollPlant has implemented a cost reduction plan expected to reduce its workforce by approximately 25%, aimed at optimizing resource allocation and extending its cash runway to support future R&D and market expansion.
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Expansion of Operations: CollPlant is set to enhance its North American distribution of rhCollagen and BioInk products through a new partnership with a U.S.-based logistics center, which will improve operational efficiency and support its growing customer base.
Innovative Developments: The company has made significant strides in its dermal filler program and has reported successful preclinical results, including the creation of a fully humanized bioprinted skin model, showcasing the potential of its rhCollagen technology as a non-animal alternative for medical research.
Financial Performance: CollPlant reported a notable increase in revenues for the third quarter of 2025, driven by sales of rhCollagen-based products and a milestone payment from AbbVie, while also implementing cost reduction measures that include a workforce reduction of approximately 25%.
Future Plans: The company aims to prioritize its collaboration with AbbVie and continue advancing its dermal filler product candidate, while also seeking strategic partnerships for the development of its regenerative breast implant product.
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS
Financial Results Announcement: CollPlant Biotechnologies will report its third-quarter financial results for 2025 on November 26, 2025, before U.S. market opening.
Company Overview: CollPlant specializes in regenerative and aesthetic medicine, focusing on 3D bioprinting and products based on non-animal-derived rhCollagen for tissue regeneration.
Partnership with Allergan: In 2021, CollPlant entered a global commercialization agreement with Allergan, a leader in the dermal filler market, for the development of dermal and soft tissue fillers.
Contact Information: For further inquiries, CollPlant's Deputy CEO & CFO, Eran Rotem, and investor relations contact, Daniel Ferry, are available for communication.
